Published in Cancer Treat Rep on May 01, 1979
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Mink cell line Mv 1 Lu (CCL 64). Focus formation and the generation of "nonproducer" transformed cell lines with murine and feline sarcoma viruses. Virology (1974) 6.53
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol (1991) 4.22
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 3.69
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Efficient transfer of highly resolved small DNA fragments from polyacrylamide gels to DBM paper. Gene (1980) 3.30
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
Biology and management of bladder cancer. N Engl J Med (1990) 2.60
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Improved methodology for analyzing local and distant recurrence. J Clin Oncol (1990) 2.21
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer. J Natl Cancer Inst (1993) 2.15
Cancer of the breast: the past decade (first of two parts). N Engl J Med (1980) 2.14
Paradigmatic shifts in the management of breast cancer. N Engl J Med (1995) 2.06
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med (1974) 2.02
Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol (1997) 2.02
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (1990) 1.93
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
The use of alternative therapies by Auckland general practitioners. N Z Med J (1990) 1.89
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res (1978) 1.88
Clinical trials with adriamycin. Cancer (1971) 1.86
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Partial purification and characterization of the SV40 T antigen. Cell (1974) 1.81
An approach to cost analysis of clinical laboratory services. Am J Clin Pathol (1978) 1.80
SV40 T antigen: partial purification and properties. Cold Spring Harb Symp Quant Biol (1975) 1.80
Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am (1997) 1.79
Spilled gallstones after laparoscopic cholecystectomy. A relevant problem? A retrospective analysis of 10,174 laparoscopic cholecystectomies. Surg Endosc (1998) 1.77
A lesson from Canada: Ontario's health insurance. N Engl J Med (1978) 1.76
Carcinoembryonic antigen: clinical correlation with chemotherapy for metastatic gastrointestinal cancer. Cancer (1974) 1.74
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Controlled multicenter trial of laparoscopic transabdominal preperitoneal hernioplasty vs Shouldice herniorrhaphy. Early results. Surg Endosc (1996) 1.71
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am (2006) 1.70
The Polycomb-group gene, extra sex combs, encodes a nuclear member of the WD-40 repeat family. EMBO J (1995) 1.69
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med (1975) 1.65
Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med (1971) 1.65
Complications of laparoscopic cholecystectomy in Switzerland. A prospective 3-year study of 10,174 patients. Swiss Association of Laparoscopic and Thoracoscopic Surgery. Surg Endosc (1998) 1.65
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol (1998) 1.59
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
The cellular biology of the Reed-Sternberg cell. Blood (1994) 1.50
Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet (1975) 1.49
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol (1996) 1.49
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
Combination cancer therapy: Presidential address. Cancer Res (1972) 1.47
A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer (1972) 1.46
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med (1972) 1.44
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res (1967) 1.44
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Who should pay for clinical research? J Clin Oncol (1990) 1.41
Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med (1985) 1.41
Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci (1974) 1.40
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med (1972) 1.40
Hormonal treatment of prostate cancer. N Engl J Med (1999) 1.39
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res (1983) 1.39
Complex regulation of early paired expression: initial activation by gap genes and pattern modulation by pair-rule genes. Development (1993) 1.39
Preoperative Nyhus classification of inguinal hernias and type-related individual hernia repair. A case for diagnostic laparoscopy. Surg Laparosc Endosc (1997) 1.39
[Early results of the initial 100 laparoscopic hernia operations under peridural anesthesia]. Schweiz Med Wochenschr (1995) 1.39
In vitro inhibition of Pseudomonas aeruginosa elastase by metal-chelating peptide derivatives. Infect Immun (1982) 1.39
Isolation and characterization of polyoma virus mutants which grow in murine embryonal carcinoma and trophoblast cells. EMBO J (1982) 1.38
Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res (1976) 1.38
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer (1971) 1.37
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice? J Clin Oncol (1985) 1.37
Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther (1972) 1.35
The present status of the vesicular hypothesis. Prog Neurobiol (1979) 1.35
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Philadelphia-chromosome-positive preleukaemic state. Lancet (1972) 1.33
The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med (1974) 1.33
Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med (1976) 1.33
Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res (1969) 1.33
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res (1989) 1.31
[Isolation of the synaptic vesicles of the electric organ of the torpedo and localization of acetylcholine at their level]. C R Acad Sci Hebd Seances Acad Sci D (1968) 1.30
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29
Studiesof a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results. Cancer (1968) 1.28